Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 2.2% in the afternoon session after the stock traded lower amid broader market weakness. U.S. stock markets began September trading on a negative note, due to concerns over tariffs and rising U.S. sovereign bond yields, which dented investor sentiment. The downward pressure appeared to continue into Wednesday's session, which saw mixed trading. While the tech-heavy Nasdaq showed gains, the Dow Jones Industrial Average was trading in negative territory. The healthcare sector, to which LeMaitre belongs, has also been facing pressure from factors like rising operational costs. In the absence of any company-specific news, the stock's dip seems to be influenced by these wider market and sector headwinds.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy LeMaitre? Access our full analysis report here, it’s free.
LeMaitre’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 28 days ago when the stock gained 9.5% on the news that the company reported better-than-expected second-quarter financial results and raised its full-year outlook. The medical device maker reported second-quarter earnings per share of $0.60 on revenue of $64.2 million, which beat Wall Street's expectations. The company's sales jumped 15% from the previous year, pushed by higher prices and a 7% increase in the number of products sold. Strong international sales for its Artegraft product also contributed to the growth. Looking ahead, LeMaitre lifted its full-year 2025 revenue forecast to $251 million and increased its earnings guidance, signaling management's confidence in continued strong performance.
LeMaitre is up 2.4% since the beginning of the year, but at $93.65 per share, it is still trading 13.3% below its 52-week high of $107.97 from November 2024. Investors who bought $1,000 worth of LeMaitre’s shares 5 years ago would now be looking at an investment worth $2,888.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
